Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

Clinical trial NCT06575257 · RECRUITING

Trial details

NCT number: NCT06575257
Sponsor: Xijing Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Prostate Cancer

Start date: 2024-05-01
Primary completion: 2026-05-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.